Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Laboratorios Richmond S.A.C.I.F.

Market Cap 126B 88.16M 75.98M 69.96M 65.69M 123M 8.34B 125M 827M 322M 4.08B 331M 324M 14.15B P/E Ratio 2024
6.08x
P/E Ratio 2025 51.6x
Enterprise Value 357B 249M 215M 198M 186M 349M 23.57B 352M 2.34B 911M 11.54B 936M 916M 40B EV / Sales 2024
3.04x
EV / Sales 2025 3.08x
Free-Float
17.54%
Yield 2024
1.5%
Yield 2025 -
05-11 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026 CI
05-07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
07/08/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
09/05/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
08/05/25 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025 CI
08/03/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
06/11/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
13/08/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
06/05/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
11/03/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
10/11/23 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
1 day-1.88%
1 week-1.57%
Current month-4.57%
1 month-1.88%
3 months-9.01%
6 months-24.76%
Current year-20.76%
1 week 1,530
Extreme 1530
1,640
1 month 1,520
Extreme 1520
1,725
Current year 1,420
Extreme 1420
2,130
1 year 945
Extreme 945
2,300
3 years 480.5
Extreme 480.5
2,300
5 years 208.5
Extreme 208.5
2,300
10 years 24.8
Extreme 24.8
2,300
Manager TitleAgeSince
President - -
General Counsel - 29/04/2025
Corporate Officer/Principal - 29/04/2025
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.88%-1.57%+7.93%+205.07% 88.16M
-0.61%-1.94%+39.00%+150.72% 1,001B
-0.20%-0.77%+51.51%+43.20% 566B
+0.40%-1.31%+16.56%+60.47% 393B
+0.18%+2.29%+24.04%+16.53% 326B
+0.23%+0.66%+25.37%+31.89% 276B
+0.41%-0.97%+25.06%+14.49% 277B
+1.97%+1.04%-41.38%-47.16% 193B
-0.77%+0.95%+17.69%+51.46% 188B
+2.36%+1.38%+14.80%+61.34% 158B
Average +0.47%+0.16%+18.06%+58.80% 337.69B
Weighted average by Cap. +0.57%-0.41%+27.88%+67.39%

Financials

2024 2025
Net sales 91.79B 64.03M 55.19M 50.82M 47.71M 89.58M 6.05B 90.53M 600M 234M 2.96B 240M 235M 10.27B 127B 88.4M 76.19M 70.15M 65.87M 124M 8.36B 125M 829M 323M 4.09B 332M 325M 14.18B
Net income 23.85B 16.63M 14.34M 13.2M 12.39M 23.27M 1.57B 23.52M 156M 60.77M 770M 62.43M 61.1M 2.67B 3.09B 2.15M 1.86M 1.71M 1.6M 3.01M 204M 3.05M 20.2M 7.87M 99.73M 8.08M 7.91M 346M
Net Debt 134B 93.23M 80.35M 73.99M 69.47M 130M 8.81B 132M 874M 341M 4.32B 350M 342M 14.96B 231B 161M 139M 128M 120M 225M 15.24B 228M 1.51B 589M 7.46B 605M 592M 25.86B
Logo Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
Employees
620
Date Price Change Volume
16/06/26 1,565.00 $ -1.88% 4,012
12/06/26 1,595.00 $ -1.85% 2,362
11/06/26 1,625.00 $ +1.88% 2,208
10/06/26 1,595.00 $ +0.31% 5,402
09/06/26 1,590.00 $ -0.31% 35,894
  1. Stock Market
  2. Stocks
  3. RICH Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!